Protein tyrosine phosphatase 1B (PTP1B), which can directly dephosphorylate both the insulin receptor and insulin receptor substrate 1 (IRS-1), thereby terminating insulin signaling, reportedly plays an important role in insulin resistance. Accumulating evidence has demonstrated that O-GlcNAc modification regulates functions of several important components of insulin signal pathway. In this study, we identified that PTP1B is modified by O-GlcNAcylation at three O-GlcNAc sites (Ser104, Ser201, and Ser386). Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3β) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells. Compared with the wild-type, intervention PTP1B O-GlcNAcylation by site-directed gene mutation inhibited PTP1B phosphatase activity, resulted in a higher level of phosphorylated Akt and GSK3β, recovered insulin sensitivity, and improved lipid deposition in HepG2 cells. Taken together, our research showed that O-GlcNAcylation of PTP1B can influence insulin signal transduction by modulating its own phosphatase activity, which participates in the process of hepatic insulin resistance.
Diabetic neuropathy (DN) is a prevalent and debilitating complication of diabetes, causing substantial morbidity and negatively impacting the quality of life for millions of individuals worldwide. The pathogenesis of DN is complex, with oxidative stress (OS) emerging as a key factor contributing to nerve damage through mechanisms like lipid peroxidation, protein modification, and DNA damage. This review examines the role of natural antioxidants in alleviating symptoms of DN, summarizes recent progress in fundamental and clinical research on antioxidants in treating DN. It emphasizes the mechanisms by which compounds such as polyphenols, terpenoids, and carotenoids counteract OS, a critical factor in the pathogenesis of DN. These antioxidants, derived from various natural sources, show promise in enhancing nerve conduction velocity, reducing neuropathic pain, and improving glucose metabolism. Clinical trials, particularly those involving alpha-lipoic acid, provide evidence supporting the benefits of antioxidant therapy in enhancing nerve function. The review highlights the necessity for further research into natural antioxidants to develop more effective treatment strategies for DN.
Background: Fatty acid-binding protein 4 (FABP4) has been demonstrated to be a predictor of early diabetic nephropathy. However, little is known about the relationship between FABP4 and diabetic retinopathy (DR). This study explored the value of FABP4 as a biomarker of DR in patients with type 2 diabetes mellitus (T2DM).Methods: A total of 238 subjects were enrolled, including 20 healthy controls and 218 T2DM patients. Serum FABP4 levels were measured using a sandwich enzyme-linked immunosorbent assay. The grade of DR was determined using fundus fluorescence angiography. Based on the international classification of DR, all T2DM patients were classified into the following three subgroups: non-DR group, non-proliferative diabetic retinopathy (NPDR) group, and proliferative diabetic retinopathy (PDR) group. Multivariate logistic regression analyses were employed to assess the correlation between FABP4 levels and DR severity.Results: FABP4 correlated positively with DR severity (r=0.225, P=0.001). Receiver operating characteristic curve analysis was used to assess the diagnostic potential of FABP4 in identifying DR, with an area under the curve of 0.624 (37% sensitivity, 83.6% specificity) and an optimum cut-off value of 76.4 μg/L. Multivariate logistic regression model including FABP4 as a categorized binary variable using the cut-off value of 76.4 μg/L showed that the concentration of FABP4 above the cut-off value increased the risk of NPDR (odds ratio [OR], 3.231; 95% confidence interval [CI], 1.574 to 6.632; P=0.001) and PDR (OR, 3.689; 95% CI, 1.306 to 10.424; P=0.014).Conclusion: FABP4 may be used as a serum biomarker for the diagnosis of DR.
Primary aldosteronism (PA), the most common cause of secondary hypertension, is associated with increased cardiovascular risks compared to essential hypertension (EH). Although PA is frequently associated with metabolic abnormalities, the role of serum uric acid (SUA) remains unclear. This study aimed to evaluate SUA as a potential biomarker for distinguishing PA from EH. A retrospective analysis of 152 PA patients and 280 age-matched EH patients hospitalized between January 2019 and February 2024 was conducted. Biochemical and clinical parameters, including SUA, aldosterone-renin ratio (ARR), potassium, and metabolic markers, were analyzed. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses assessed SUA’s diagnostic accuracy for PA. Subgroup analyses were conducted by sex and menopausal status. The disease severity of PA patients was further evaluated using the Primary Aldosteronism Severity Classification (PASC). PA patients exhibited significantly lower SUA levels compared to EH (P < 0.001), independent of age, BMI, and renal function. SUA levels showed a significant inverse correlation with PASC severity grades (Spearman’s rho = -0.42, P < 0.001) and no significant difference was observed between APA and IHA subtypes. SUA ≤ 361 µmol/L was strongly associated with PA, with an ROC AUC of 0.750. The ROC curve analysis revealed an AUC of 0.766 for SUA in screening PA among males (optimal cut-off: 364 µmol/L). For premenopausal female patients, the AUC was 0.725 (cut-off: 325 µmol/L), and for postmenopausal females, the AUC was 0.764 (cut-off: 358 µmol/L). The diagnostic performance of SUA surpassed that of the PFK score (AUC: 0.732). Reduced SUA levels are independently associated with PA, suggesting its potential utility as an auxiliary biomarker to raise suspicion for PA, particularly in settings with limited access to ARR testing. Prospective studies are required to validate its clinical relevance and mechanistic basis. Not applicable.